Near-patient SARS-CoV-2 molecular platforms: new-old tools for new-old problems
Publication date: Available online 8 October 2020Source: The Lancet Respiratory MedicineAuthor(s): Luke S P Moore
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
Authors: Hui KK PMID: 33034297 [PubMed - as supplied by publisher]
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): G. Alvarez Bravo, L. RamióTorrentà
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): N. Morollón, R. Belvís, A. De Dios, N. Pagès, C. González-Oria, G. Latorre, S. Santos-Lasaosa
Publication date: Available online 10 October 2020Source: Journal of Hospital InfectionAuthor(s): Hisakazu Yano, Ryuichi Nakano, Yuki Suzuki, Akiyo Nakano, Kei Kasahara, Hiroshi Hosoi
Authors: Yepes-Pérez AF, Herrera-Calderon O, Sánchez-Aparicio JE, Tiessler-Sala L, Maréchal JD, Cardona-G W Abstract COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2. Presently, there is no effective treatment for COVID-19. As part of the worldwide efforts to find efficient therapies and preventions, it has been reported the crystalline structure of the SARS-CoV-2 main protease Mpro (also called 3CLpro) bound to a synthetic inhibitor, which represents a major druggable target. The druggability of Mpro could be used for discovering drugs to treat COVID-19. A multil...
Conclusions: Early results of universal preoperative screening for COVID-19 demonstrates a low incidence and high rate of asymptomatic patients. Health care professionals, especially those at higher risk for the virus, should be aware of the challenges related to screening based solely on symptoms or travel history and consider universal screening for patients undergoing elective surgery. Level of Evidence: Level II.